• Miklos Lipcsey, Jyrki Tenhunen, Soeren E Pischke, Anne Kuitunen, Hans Flaatten, Lina De Geer, Jan Sjölin, Robert Frithiof, Michelle S Chew, Stepani Bendel, Rafael Kawati, Anders Larsson, Tom Eirik Mollnes, Tor Inge Tønnessen, and Sten Rubertsson.
• Hedenstierna Laboratory, Department of Surgical Sciences/Anaesthesiology and Intensive Care Medicine, Uppsala University, Uppsala, Sweden.
• Shock. 2020 Aug 1; 54 (2): 224-231.

PurposeLipopolysaccharides (LPS) are presumed to contribute to the inflammatory response in sepsis. We investigated if extracorporeal Alteco LPS Adsorber for LPS removal in early gram-negative septic shock was feasible and safe. Also, effects on endotoxin level, inflammatory response, and organ function were assessed.MethodsA pilot, double-blinded, randomized, Phase IIa, feasibility clinical investigation was undertaken in six Scandinavian intensive care units aiming to allocate 32 septic shock patients with abdominal or urogenital focus on LPS Adsorber therapy or a Sham Adsorber, therapy without active LPS binding. The study treatment was initiated within 12 h of inclusion and given for 6 h daily on first 2 days. LPS was measured in all patients.ResultsThe investigation was terminated after 527 days with eight patients included in the LPS Adsorber group and seven in the Sham group. Twenty-one adverse effects, judged not to be related to the device, were reported in three patients in the LPS Adsorber group and two in the Sham group. Two patients in the Sham group and no patients in the LPS Adsorber group died within 28 days. Plasma LPS levels were low without groups differences during or after adsorber therapy. The changes in inflammatory markers and organ function were similar in the groups.ConclusionsIn a small cohort of patients with presumed gram-negative septic shock, levels of circulating endotoxin were low and no adverse effects within 28 days after LPS adsorber-treatment were observed. No benefit compared with a sham device was seen when using a LPS adsorber in addition to standard care.Trial RegistrationClinicaltrials.gov NCT02335723. Registered: November 28, 2014.

16 keywords...

hide…